Changes in intestinal microbiota in postmenopausal oestrogen receptor-positive breast cancer patients treated with (neo)adjuvant chemotherapy.

Autor: Aarnoutse R; GROW - School for Oncology and Developmental Biology, Maastricht University, Maastricht, the Netherlands. romyaarnoutse@gmail.com.; Department of Surgery, Maastricht University Medical Centre, Maastricht, the Netherlands. romyaarnoutse@gmail.com., Ziemons J; GROW - School for Oncology and Developmental Biology, Maastricht University, Maastricht, the Netherlands.; Department of Surgery, Maastricht University Medical Centre, Maastricht, the Netherlands., Hillege LE; GROW - School for Oncology and Developmental Biology, Maastricht University, Maastricht, the Netherlands.; Department of Surgery, Maastricht University Medical Centre, Maastricht, the Netherlands., de Vos-Geelen J; GROW - School for Oncology and Developmental Biology, Maastricht University, Maastricht, the Netherlands.; Department of Internal Medicine, Division of Medical Oncology, Maastricht University Medical Centre, Maastricht, the Netherlands., de Boer M; GROW - School for Oncology and Developmental Biology, Maastricht University, Maastricht, the Netherlands.; Department of Internal Medicine, Division of Medical Oncology, Maastricht University Medical Centre, Maastricht, the Netherlands., Bisschop SMP; Department of Surgery, Maastricht University Medical Centre, Maastricht, the Netherlands., Vriens BEPJ; Department of Medical Oncology, Catharina Hospital, Eindhoven, the Netherlands., Vincent J; Department of Medical Oncology, Elkerliek Hospital, Helmond, the Netherlands., van de Wouw AJ; Department of Medical Oncology, VieCuri Medical Centre, Venlo, the Netherlands., Le GN; Department of Medical Microbiology, Maastricht University Medical Centre, Maastricht, the Netherlands., Venema K; NUTRIM - School of Nutrition and Translational research In Metabolism, Maastricht University, Maastricht, the Netherlands.; Centre for Healthy Eating & Food Innovation, Maastricht University - campus Venlo, Venlo, the Netherlands.; Euregional Microbiome Center, Maastricht, the Netherlands., Rensen SS; Department of Surgery, Maastricht University Medical Centre, Maastricht, the Netherlands.; NUTRIM - School of Nutrition and Translational research In Metabolism, Maastricht University, Maastricht, the Netherlands., Penders J; Department of Medical Microbiology, Maastricht University Medical Centre, Maastricht, the Netherlands.; NUTRIM - School of Nutrition and Translational research In Metabolism, Maastricht University, Maastricht, the Netherlands.; Euregional Microbiome Center, Maastricht, the Netherlands., Smidt ML; GROW - School for Oncology and Developmental Biology, Maastricht University, Maastricht, the Netherlands.; Department of Surgery, Maastricht University Medical Centre, Maastricht, the Netherlands.
Jazyk: angličtina
Zdroj: NPJ breast cancer [NPJ Breast Cancer] 2022 Jul 29; Vol. 8 (1), pp. 89. Date of Electronic Publication: 2022 Jul 29.
DOI: 10.1038/s41523-022-00455-5
Abstrakt: This clinical study explored the associations between the intestinal microbiota, chemotherapy toxicity, and treatment response in postmenopausal oestrogen receptor positive breast cancer patients.Oestrogen receptor positive postmenopausal breast cancer patients were prospectively enroled in a multicentre cohort study and treated with 4 cycles of (neo)adjuvant adriamycin, cyclophosphamide (AC) followed by 4 cycles of docetaxel (D). Patients collected a faecal sample and completed a questionnaire before treatment, during AC, during D, and after completing AC-D. Chemotherapy toxicity and tumour response were determined. Intestinal microbiota was analysed by amplicon sequencing of the 16 S rRNA V4 gene-region. In total, 44 patients, including 18 neoadjuvant patients, were included, and 153 faecal samples were collected before AC-D (n = 44), during AC (n = 43), during D (n = 29), and after AC-D treatment (n = 37), 28 participants provided all four samples. In the whole group, observed species richness reduced during treatment (p = 0.042). The abundance of Proteobacteria, unclassified Enterobacterales, Lactobacillus, Ruminococcaceae NK4A214 group, Marvinbryantia, Christensenellaceae R7 group, and Ruminococcaceae UCG-005 changed significantly over time. Patients with any grade diarrhoea during docetaxel treatment had a significantly lower observed species richness compared to patients without diarrhoea. In the small group neoadjuvant treated patients, pathologic response was unrelated to baseline intestinal microbiota richness, diversity and composition. While the baseline microbiota was not predictive for pathologic response in a rather small group of neoadjuvant treated patients in our study, subsequent shifts in microbial richness, as well as the abundance of specific bacterial taxa, were observed during AC-D treatment in the whole group and the neoadjuvant group.
(© 2022. The Author(s).)
Databáze: MEDLINE
Externí odkaz: